Nilotinib

• Description:

  Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

• Product Name Alternative:

  AMN107

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Nilotinib.html

• Purity:

  99.94

• Solubility:

  1 M HCl : ≥ 100 mg/mL|DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(NC1=CC(C(F)(F)F)=CC(N2C=NC(C)=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3

• Molecular Formula:

  C28H22F3N7O

• Molecular Weight:

  529.52

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109 (5) :2112-20.|[2]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9 (9) :e107613.|[3]Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21 (44) :12576-85.|[4]Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106 (9) :2632-2641.|[5]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Chem Biol. 2016 Apr 15;11 (4) :992-1000.|Biomaterials. 2022 Oct:289:121800.|Biomed Chromatogr. 2019 Dec;33 (12) :e4674.|Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomolecules. 2022 Jun 11;12 (6) :819.|bioRxiv. 2024 Dec 20:2024.12.19.629301.|bioRxiv. 2024 Dec 22:2024.12.21.629902.|bioRxiv. 2024 May 8:2024.05.07.592424.|bioRxiv. 2025 February 26.|bioRxiv. 2025 Sep 30.|Blood Vessel Thromb Hemost. 2025 Nov 17.|Br J Cancer. 2022 Mar;126 (5) :778-790.|Breast Cancer Res. 2023 May 5;25 (1) :51.|Cancer Biol Ther. 2019;20 (6) :877-885.|Cancer Lett. 2024 Aug 1:217150.|Cancer Med. 2016 Nov;5 (11) :3223-3234.|Cancer Res. 2025 Jan 2;85 (1) :101-117.|Cell Death Dis. 2021 Sep 25;12 (10) :875.|Cell Mol Immunol. 2024 Aug;21 (8) :856-872.|Cell Rep Med. 2025 Apr 2:102053.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Diseases. 2023 Oct 23;11 (4) :147.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Eur J Pharmacol. 2021 Apr 15:897:173944.|Glia. 2022 Jun;70 (6) :1084-1099.|Harvard Medical School LINCS LIBRARY|Int J Mass Spectrom. 442 (2019) 44-50.|J Pharm Sci. 2017 Sep;106 (9) :2632-2641.|Leuk Lymphoma. 2015;56 (8) :2416-23. |Mol Med Rep. 2025 Jun;31 (6) :165.|Oncotarget. 2018 Apr 24;9 (31) :22158-22183. |Patent. US20190084960A1|Patent. US20210299273A1.|Phytomedicine. 2025 Sep 25:148:157332.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Preprint. 2024 Nov 06.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Stem Cell Reports. 2019 May 14;12 (5) :996-1006. |Target Oncol. 2020 Oct;15 (5) :659-671.|Technical University of Munich. 24.01.2018.|Toxicol Lett. 2022 Jul 15:365:11-23.|Toxicology. 2024 May 15:505:153830.|Xenobiotica. 2018 Oct;48 (10) :1059-1071. |bioRxiv. January 25, 2022.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Drug Metab Pharmacokinet. 2020 Feb;35 (1) :102-110.

• CAS Number:

  [641571-10-0]